Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
AML/MDS
Interventions
BIOLOGICAL

Mana 312

"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

30309

Northside Hospital - Atlanta, Atlanta

37203

Tennessee Oncology, Nashville

37232

Vanderbilt - Ingram Cancer Center, Nashville

66103

University of Kansas Cancer Center, Kansas City

78229

Texas Transplant/Methodist Hospital, San Antonio

78704

Texas Transplant/St David's South Austin, Austin

80218

Colorado Blood Cancer Institute, Denver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mana Therapeutics

INDUSTRY